Every year, between 250,000 and 500,000 people around the world sustain a spinal cord injury (SCI). Four industry figureheads came together last week to address this challenge in our exclusive roundtable. Catch up now on YouTube or read on for our highlights from the debate. Read More
Each year, hundreds of thousands of people suffer from spinal cord injury. In addition, poor medical care and the lack of availability of effective treatments contribute to an increase in SCI patient mortality and disability. With rising numbers of workplace accidents, road accidents, and other medical conditions, the global SCI
The Company will be participating in the upcoming 2022 Bio-Europe Conference (“Bio-Europe”) in Leipzig, Germany, which commences on October 24th and ends on October 26th. Bio-Europe is regarded as one of Europe’s largest gathering of professionals in the biopharma industry. Over 4000 attendees and more than 2200 companies from around
Calgary, Alberta and Oxford, United Kingdom–(Newsfile Corp. – October 12, 2022) – NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the “Company” or “NurExone”), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal cord injuries, is pleased to announce that the Company’s wholly-owned subsidiary, NurExone Biologic Ltd., signed
